Intellia reported Phase 3 success for lonvo-z (lonvoguran ziclumeran) in hereditary angioedema, positioning the treatment toward regulatory filing for an in vivo CRISPR approach. The company said the therapy met the primary endpoint in the HAELO study, reducing swelling attacks by 87% versus placebo at six months. Reporting also highlights that just over 60% of treated patients were attack-free during the study window compared with 11% for placebo, with no serious safety signals mentioned in the coverage. Intellia is described as having initiated a rolling submission with regulators. The results establish a critical market test case for in vivo gene editing therapies, particularly for one-time dosing as a differentiating commercial value proposition.